PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $56.72 million.

GUIDANCE:

PTC Therapeutics sees Q2 2018 net product revenue of $260-295 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.